REDWOOD CITY, Calif.--(BUSINESS WIRE)--iSchemaView, the leader in cerebrovascular imaging analysis, today announced that the company has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID imaging platform in Australia and New Zealand. Hospitals and clinics that treat ischemic stroke in these countries will now have access to RAPID’s automated CTP, MR, CTA and ASPECTS solutions, with support from DIA’s customer service specialists in the region.
iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The prior treatment window for mechanical thrombectomy was up to six hours, however select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.
“More than 450 stroke centers and hospitals all over North America and Europe are using the RAPID platform to provide optimal care to patients suffering from ischemic stroke. We are excited to partner with DIA to bring these solutions to Australia and New Zealand,” said Don Listwin, CEO of iSchemaView. “Our mission is to help health care systems address and treat more stroke patients than ever before, and this partnership will greatly expand the population served by RAPID technology.”
The RAPID neuroimaging platform creates high-quality images from non-contrast CT, CT angiography, CT perfusion and MRI diffusion and perfusion studies. The software provides an intuitive and easily interpretable real-time view of brain perfusion, allowing physicians to determine lesion volumes for a wide variety of different thresholds. The platform includes four different imaging products, tailored to the particular needs of different types of facilities:
- RAPID MRI provides fully automated, easy to interpret diffusion and perfusion maps that identify brain areas with low ADC values, as well as delayed contrast arrival. RAPID MRI perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds.
- RAPID CT perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. Regions are color coded and the volumes of interest are automatically measured. Maps (including mismatch maps) of the severity of Tmax delays are provided using a four-color-coded scale.
- RAPID CTA automatically provides clear, easy to interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles.
- RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score.
For more information about working with RAPID in Australia or New Zealand, contact Phillip Cahill of DIA at 03-9584-9533 or at firstname.lastname@example.org.
About Diagnostic Imaging Australia
Diagnostic Imaging Australia is one of the leading providers of Advanced Visualisation software for the Medical Imaging community in Australia and New Zealand.
Specializing in advanced technology products, such as TeraRecon Advanced Visualisation, EnvoyAI and Cydar Cloud, Diagnostic Imaging Australia is pleased to distribute and support iSchemaView’s RAPID software, throughout Australia and New Zealand.
For more information, visit http://www.diagnosticimaging.com.au.
iSchemaView is the leader in cerebrovascular imaging analysis, delivering the proven software tools that healthcare professionals around the world use to successfully identify and treat more stroke patients than ever before. Already installed in over 400 hospitals and stroke centers, iSchemaView’s RAPID (automated CTP, MR, CTA and ASPECTS), is the most advanced brain imaging platform. In clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early and late window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN and DEFUSE 3. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit www.iRAPID.com.